Literature DB >> 3416075

Cytogenetic studies and their prognostic significance in agnogenic myeloid metaplasia: a report on 47 cases.

J L Demory1, B Dupriez, P Fenaux, J L Laï, R Beuscart, J P Jouet, M Deminatti, F Bauters.   

Abstract

Cytogenetic analysis was performed in 47 newly diagnosed patients with agnogenic myeloid metaplasia (AMM); 32 had a normal karyotype (68%, group I), whereas 15 had clonal abnormalities (32%, group II). The most frequent abnormal findings were a 20q- deletion in six cases (either alone or within complex anomalies), interstitial 13q- deletion in three cases (and monosomy 13 in one case), and acquired trisomy 21 or 21p+ in three cases. Four cases exhibited complex aberrations involving several chromosomes, sometimes with a mosaicism. In two patients with an initial abnormal karyotype, further cytogenetic analysis during the disease course showed the appearance of additional clonal anomalies, and particularly of a probable Philadelphia (Ph1) variant in one case. Treatment was essentially supportive. Survival was significantly shorter in group II (median, 30 months) compared with group I (median, not reached at 6 years; P = .015). In univariate analysis, other parameters significantly associated with a poor prognosis (P less than .05) were higher age, anemia, and increased percentage of circulating blasts. However, in a multivariate analysis, only cytogenetic abnormalities and age retained their independent prognostic value.

Entities:  

Mesh:

Year:  1988        PMID: 3416075

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  Treatment With JAK Inhibitors in Myelofibrosis Patients Nullifies the Prognostic Impact of Unfavorable Cytogenetics.

Authors:  Vincent T Ma; Philip S Boonstra; Kamal Menghrajani; Cecelia Perkins; Krisstina L Gowin; Ruben A Mesa; Jason R Gotlib; Moshe Talpaz
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2018-03-02

Review 2.  Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors.

Authors:  Vikas Gupta; Parameswaran Hari; Ronald Hoffman
Journal:  Blood       Date:  2012-06-14       Impact factor: 22.113

Review 3.  Routine and specialised techniques in the diagnosis of haematological neoplasms.

Authors:  B J Bain
Journal:  J Clin Pathol       Date:  1995-06       Impact factor: 3.411

4.  Usefulness of spleen volume measured by computed tomography for predicting clinical outcome in primary myelofibrosis.

Authors:  Moo-Kon Song; Joo-Seop Chung; Sung-Nam Lim; Gyeong-Won Lee; Sang-Min Lee; Nam-Kyung Lee; Jae-Cheol Choi; So-Yeon Oh
Journal:  Int J Hematol       Date:  2016-06-27       Impact factor: 2.490

5.  The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course.

Authors:  Constantine S Tam; Lynne V Abruzzo; Katherine I Lin; Jorge Cortes; Alice Lynn; Michael J Keating; Deborah A Thomas; Sherry Pierce; Hagop Kantarjian; Srdan Verstovsek
Journal:  Blood       Date:  2009-01-08       Impact factor: 22.113

6.  Primary myelofibrosis: a detailed statistical analysis of the clinicopathological variables influencing survival.

Authors:  S Rupoli; L Da Lio; S Sisti; G Campanati; A Salvi; M F Brianzoni; S D'Amico; A Cinciripini; P Leoni
Journal:  Ann Hematol       Date:  1994-04       Impact factor: 3.673

7.  Factors affecting prognosis in myelofibrosis.

Authors:  Francesco Onida
Journal:  F1000 Med Rep       Date:  2009-07-08

8.  Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients.

Authors:  Ayalew Tefferi; Maura Nicolosi; Mythri Mudireddy; Terra L Lasho; Naseema Gangat; Kebede H Begna; Curtis A Hanson; Rhett P Ketterling; Animesh Pardanani
Journal:  Leukemia       Date:  2018-02-02       Impact factor: 11.528

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.